Last updated on August 2012

RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma


Brief description of study

RTOG 1010: A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma

Detailed Study Description

For more information please visit: http://clinicaltrials.gov/ct2/show/NCT01196390?term=RTOG+1010&rank=1

Clinical Study Identifier: TX136165

Contact Investigators or Research Sites near you

Start Over

Patricia Green

Memorial University Medical Center
Savannah, GA USA
  Connect »